101
|
Haas R, Dücker KH, Küppers HA. Aktivitätskoeffizienten und Dissoziationskonstanten wäβriger Salpetersäure und Überchlorsäure. ACTA ACUST UNITED AC 2014. [DOI: 10.1002/bbpc.19650690202] [Citation(s) in RCA: 31] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/08/2022]
|
102
|
Pommer B, Mailath-Pokorny G, Haas R, Busenlechner D, Fürhauser R, Watzek G. Patients' preferences towards minimally invasive treatment alternatives for implant rehabilitation of edentulous jaws. EUROPEAN JOURNAL OF ORAL IMPLANTOLOGY 2014; 7 Suppl 2:S91-S109. [PMID: 24977244] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/03/2023]
Abstract
PURPOSE To evaluate patient satisfaction, oral health-related quality of life, and patients' preferences towards minimally invasive treatment options for graftless rehabilitation of complete edentulism by means of dental implants. MATERIAL AND METHODS A MEDLINE search of literature in the English language up to the year 2013 was performed to summarise current evidence from the patient's perspective. The final selection included 37 studies reporting on minimally invasive implant treatment of 648 edentulous maxillae and 791 edentulous mandibles in 1328 patients, via a total of 5766 implants. RESULTS Patient satisfaction averaged 91% with flapless implant placement (range: 77 to 100%), 89% with short implants, 87% with narrow-diameter implants (range: 80 to 93%), 90% with a reduced number of implants (range: 77 to 100%), 94% with tilted implant placement (range: 58 to 100%), and 83% with zygomatic fixtures (range: 50 to 97%). Indirect comparison yielded patient preference towards tilted implant placement compared to a reduced number of implants (P = 0.036), as well as to zygomatic implants (P = 0.001). CONCLUSIONS While little evidence on patients' preferences towards minimally invasive treatment alternatives vs. bone augmentation surgery could be identified from within-study comparison, it may be concluded that patient satisfaction with graftless solutions for implant rehabilitation of completely edentulous jaws is generally high. Comparative effectiveness research is needed to substantiate their positive appeal to potential implant patients and possible reduction of the indication span for invasive bone graft surgery.
Collapse
|
103
|
Göbel U, Haas R, Calaminus G, Botorek P, Schmidt P, Teske C, Schönberger S, Schneider D, Harms D. Testicular Germ Cell Tumors in Boys <10 Years: Results of the Protocol MAHO 98 in Respect to Surgery and Watch & Wait Strategy. KLINISCHE PADIATRIE 2013; 225:296-302. [DOI: 10.1055/s-0033-1355427] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
104
|
Reisswig C, Ott CD, Abdikamalov E, Haas R, Mösta P, Schnetter E. Formation and coalescence of cosmological supermassive-black-hole binaries in supermassive-star collapse. PHYSICAL REVIEW LETTERS 2013; 111:151101. [PMID: 24160586 DOI: 10.1103/physrevlett.111.151101] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/29/2013] [Indexed: 05/27/2023]
Abstract
We study the collapse of rapidly rotating supermassive stars that may have formed in the early Universe. By self-consistently simulating the dynamics from the onset of collapse using three-dimensional general-relativistic hydrodynamics with fully dynamical spacetime evolution, we show that seed perturbations in the progenitor can lead to the formation of a system of two high-spin supermassive black holes, which inspiral and merge under the emission of powerful gravitational radiation that could be observed at redshifts z is approximately equal or > to 10 with the DECIGO or Big Bang Observer gravitational-wave observatories, assuming supermassive stars in the mass range 10(4)-10(6)M[symbol: see text]. The remnant is rapidly spinning with dimensionless spin a*=0.9. The surrounding accretion disk contains ~10% of the initial mass.
Collapse
|
105
|
Lindroos J, Husa J, Mitterer G, Haschemi A, Rauscher S, Haas R, Gröger M, Loewe R, Kohrgruber N, Schrögendorfer KF, Prager G, Beck H, Pospisilik JA, Zeyda M, Stulnig TM, Patsch W, Wagner O, Esterbauer H, Bilban M. Human but not mouse adipogenesis is critically dependent on LMO3. Cell Metab 2013; 18:62-74. [PMID: 23823477 PMCID: PMC3701325 DOI: 10.1016/j.cmet.2013.05.020] [Citation(s) in RCA: 49] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/19/2012] [Revised: 03/06/2013] [Accepted: 05/17/2013] [Indexed: 11/25/2022]
Abstract
Increased visceral fat is associated with a high risk of diabetes and metabolic syndrome and is in part caused by excessive glucocorticoids (GCs). However, the molecular mechanisms remain undefined. We now identify the GC-dependent gene LIM domain only 3 (LMO3) as being selectively upregulated in a depot-specific manner in human obese visceral adipose tissue, localizing primarily in the adipocyte fraction. Visceral LMO3 levels were tightly correlated with expression of 11β-hydroxysteroid dehydrogenase type-1 (HSD11B1), the enzyme responsible for local activation of GCs. In early human adipose stromal cell differentiation, GCs induced LMO3 via the GC receptor and a positive feedback mechanism involving 11βHSD1. No such induction was observed in murine adipogenesis. LMO3 overexpression promoted, while silencing of LMO3 suppressed, adipogenesis via regulation of the proadipogenic PPARγ axis. These results establish LMO3 as a regulator of human adipogenesis and could contribute a mechanism resulting in visceral-fat accumulation in obesity due to excess glucocorticoids.
Collapse
|
106
|
Haas R, Marelli-Berg F, Mauro C. In the eye of the storm: T cell behavior in the inflammatory microenvironment. AMERICAN JOURNAL OF CLINICAL AND EXPERIMENTAL IMMUNOLOGY 2013; 2:146-155. [PMID: 23885332 PMCID: PMC3714175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Received: 05/23/2013] [Accepted: 06/07/2013] [Indexed: 06/02/2023]
Abstract
Coordinated unfolding of innate and adaptive immunity is key to the development of protective immune responses. This functional integration occurs within the inflamed tissue, a microenvironment enriched with factors released by innate and subsequently adaptive immune cells and the injured tissue itself. T lymphocytes are key players in the ensuing adaptive immunity and their proper function is instrumental to a successful outcome of immune protection. The site of inflammation is a "harsh" environment in which T cells are exposed to numerous factors that might influence their behavior. Low pH and oxygen concentration, high lactate and organic acid content as well as free fatty acids and reactive oxygen species are found in the inflammatory microenvironment. All these components affect T cells as well as other immune cells during the immune response and impact on the development of chronic inflammation. We here overview the effects of a number of factors present in the inflammatory microenvironment on T cell function and migration and discuss the potential relevance of these components as targets for therapeutic intervention in autoimmune and chronic inflammatory diseases.
Collapse
|
107
|
Nachtkamp K, Kündgen A, Neukirchen J, Strupp C, Schroeder T, Haas R, Kobbe G, Gattermann N, Germing U. P-255 Inclusion criteria of clinical trials do not meet the real MDS population. A registry-based simulation. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70302-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
108
|
Zipperer E, Neukirchen J, Strupp C, Schroeder T, Abdu A, Kündgen A, Hildebrandt B, Schulte K, Haas R, Gattermann N, Germing U. P-049 Clinical and prognostic relationship of CMML to MDS and MPS. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70098-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
109
|
Geyh S, Cadeddu R, Fröbel J, Hünerlitürkoglu A, Kündgen A, Hermsen D, Zilkens C, Fenk R, Kobbe G, Germing U, Haas R, Schroeder T. P-230 MDS-derived mesenchymal stromal cells are phenotypically, structurally and epigenetically altered resulting in insufficient stromal support for CD34+ HSPC. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70277-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
110
|
Lauseker M, Kuendgen A, Giagounidis A, Aul C, Haas R, Schlenk R, Haase D, Platzbecker U, Hasford J, Germing U. P-101 Influence of WHO categories and gender on the prognosis of MDS del(5q) patients. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70149-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
111
|
Schemenau J, Baldus S, Anlauf M, Blum S, Nachtkamp K, Neukirchen J, Strupp C, Haas R, Gattermann N, Germing U. P-093 Hypoplastic myelodysplastic syndromes are not a specific clinical entity. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70142-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
112
|
Fröbel J, Hartwig S, Germing U, Kündgen A, Zilkens C, Schroeder T, Haas R, Czibere A, Lehr S. O-004 New minimal-invasive diagnostic procedures for patients with myelodysplastic syndromes by profiling the deep serum proteome. Leuk Res 2013. [DOI: 10.1016/s0145-2126(13)70026-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
113
|
Geyh S, Oz S, Cadeddu RP, Fröbel J, Brückner B, Kündgen A, Fenk R, Bruns I, Zilkens C, Hermsen D, Gattermann N, Kobbe G, Germing U, Lyko F, Haas R, Schroeder T. Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia 2013; 27:1841-51. [PMID: 23797473 DOI: 10.1038/leu.2013.193] [Citation(s) in RCA: 169] [Impact Index Per Article: 15.4] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2013] [Revised: 06/03/2013] [Accepted: 06/19/2013] [Indexed: 01/09/2023]
Abstract
Ineffective hematopoiesis is a major characteristic of myelodysplastic syndromes (MDS) causing relevant morbidity and mortality. Mesenchymal stromal cells (MSC) have been shown to physiologically support hematopoiesis, but their contribution to the pathogenesis of MDS remains elusive. We show that MSC from patients across all MDS subtypes (n=106) exhibit significantly reduced growth and proliferative capacities accompanied by premature replicative senescence. Osteogenic differentiation was significantly reduced in MDS-derived MSC, indicated by cytochemical stainings and reduced expressions of Osterix and Osteocalcin. This was associated with specific methylation patterns that clearly separated MDS-MSC from healthy controls and showed a strong enrichment for biological processes associated with cellular phenotypes and transcriptional regulation. Furthermore, in MDS-MSC, we detected altered expression of key molecules involved in the interaction with hematopoietic stem and progenitor cells (HSPC), in particular Osteopontin, Jagged1, Kit-ligand and Angiopoietin as well as several chemokines. Functionally, this translated into a significantly diminished ability of MDS-derived MSC to support CD34+ HSPC in long-term culture-initiating cell assays associated with a reduced cell cycle activity. Taken together, our comprehensive analysis shows that MSC from all MDS subtypes are structurally, epigenetically and functionally altered, which leads to impaired stromal support and seems to contribute to deficient hematopoiesis in MDS.
Collapse
|
114
|
Dolderer J, Medved F, Haas R, Siegel-Axel D, Schiller S, Schaller HE. Angiogenese und Vaskularisation beim Tissue Engineering von Fettgewebe. HANDCHIR MIKROCHIR P 2013; 45:99-107. [DOI: 10.1055/s-0032-1329944] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022] Open
|
115
|
Schroeder T, Czibere A, Platzbecker U, Bug G, Uharek L, Luft T, Giagounidis A, Zohren F, Bruns I, Wolschke C, Rieger K, Fenk R, Germing U, Haas R, Kröger N, Kobbe G. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia 2013; 27:1229-35. [PMID: 23314834 DOI: 10.1038/leu.2013.7] [Citation(s) in RCA: 170] [Impact Index Per Article: 15.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
The combination of azacitidine and donor lymphocyte infusions (DLI) as first salvage therapy for relapse after allogeneic transplantation (allo-HSCT) was studied in 30 patients with acute myeloid leukemia (AML; n=28) or myelodysplastic syndromes (MDS; n=2) within a prospective single-arm multicenter phase-II trial. Treatment schedule contained up to eight cycles azacitidine (100 mg/m(2)/day, days 1-5, every 28 days) followed by DLI (from 1-5 × 10(6) to 1-5 × 10(8) CD3(+)cells/kg) after every second azacitidine cycle. A median of three courses azacitidine (range 1-8) were administered, and 22 patients (73%) received DLI. Overall response rate was 30%, including seven complete remissions (CRs, 23%) and two partial remissions (7%). Five patients remain in CR for a median of 777 days (range 461-888). Patients with MDS or AML with myelodysplasia-related changes were more likely to respond (P=0.011), and a lower blast count (P=0.039) as well as high-risk cytogenetics (P=0.035) correlated with the likelihood to achieve CR. Incidence of acute and chronic graft-versus-host disease was 37% and 17%, respectively. Neutropenia and thrombocytopenia grade III/IV occurred during 65% and 63% of treatment cycles, while infections were the most common grade III/IV non-hematological toxicity. Azacitidine and DLI as salvage therapy is safe, induces long-term remissions and may become an alternative for patients with AML or MDS relapsing after allo-HSCT.
Collapse
|
116
|
Shcherbakov R, Pe’er A, Reynolds C, Haas R, Bode T, Laguna P. Prompt emission from tidal disruptions of white dwarfs by intermediate mass black holes. EPJ WEB OF CONFERENCES 2012. [DOI: 10.1051/epjconf/20123902007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
117
|
Haschemi A, Kosma P, Gille L, Evans C, Burant C, Starkl P, Knapp B, Haas R, Schmid J, Jandl C, Amir S, Lubec G, Park J, Esterbauer H, Bilban M, Brizuela L, Pospisilik J, Otterbein L, Wagner O. The sedoheptulose kinase CARKL directs macrophage polarization through control of glucose metabolism. Cell Metab 2012; 15:813-26. [PMID: 22682222 PMCID: PMC3370649 DOI: 10.1016/j.cmet.2012.04.023] [Citation(s) in RCA: 419] [Impact Index Per Article: 34.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/21/2011] [Revised: 11/18/2011] [Accepted: 04/26/2012] [Indexed: 12/17/2022]
Abstract
Immune cells are somewhat unique in that activation responses can alter quantitative phenotypes upwards of 100,000-fold. To date little is known about the metabolic adaptations necessary to mount such dramatic phenotypic shifts. Screening for novel regulators of macrophage activation, we found nonprotein kinases of glucose metabolism among the most enriched classes of candidate immune modulators. We find that one of these, the carbohydrate kinase-like protein CARKL, is rapidly downregulated in vitro and in vivo upon LPS stimulation in both mice and humans. Interestingly, CARKL catalyzes an orphan reaction in the pentose phosphate pathway, refocusing cellular metabolism to a high-redox state upon physiological or artificial downregulation. We find that CARKL-dependent metabolic reprogramming is required for proper M1- and M2-like macrophage polarization and uncover a rate-limiting requirement for appropriate glucose flux in macrophage polarization.
Collapse
|
118
|
Germing U, Kündgen A, Haas R, Gattermann N. Myelodysplastische Syndrome (MDS). Dtsch Med Wochenschr 2012; 137:183-5. [PMID: 22278686 DOI: 10.1055/s-0031-1292887] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
119
|
Germing U, Lauseker M, Hildebrandt B, Symeonidis A, Cermak J, Fenaux P, Kelaidi C, Pfeilstöcker M, Nösslinger T, Sekeres M, Maciejewski J, Haase D, Schanz J, Seymour J, Kenealy M, Weide R, Lübbert M, Platzbecker U, Valent P, Götze K, Stauder R, Blum S, Kreuzer KA, Schlenk R, Ganser A, Hofmann WK, Aul C, Krieger O, Kündgen A, Haas R, Hasford J, Giagounidis A. Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): A multicenter study. Leukemia 2012; 26:1286-92. [PMID: 22289990 DOI: 10.1038/leu.2011.391] [Citation(s) in RCA: 96] [Impact Index Per Article: 8.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/21/2023]
|
120
|
Laguna P, Haas R, Shcherbakov R, Bode T. Tidal disruption of white dwarfs by intermediate mass black holes. EPJ WEB OF CONFERENCES 2012. [DOI: 10.1051/epjconf/20123907002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
121
|
Morgalla MH, Haas R, Grözinger G, Thiel C, Thiel K, Schuhmann MU, Schenk M. Experimental comparison of the measurement accuracy of the Licox(®) and Raumedic (®) Neurovent-PTO brain tissue oxygen monitors. ACTA NEUROCHIRURGICA. SUPPLEMENT 2012; 114:169-72. [PMID: 22327686 DOI: 10.1007/978-3-7091-0956-4_32] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
BACKGROUND Only a few experimental reports are available on the direct comparison of Licox(®) and Raumedic(®)-Neurovent-PTO brain tissue oxygen pressure (P(br)O(2)) monitors. We compared the two systems regarding their measurement properties under experimental in vitro and in vivo conditions. MATERIALS AND METHODS Eight Licox(®) and Raumedic(®) Neurovent-PTO(®) sensors were tested for 10 min at 37°C, atmospheric pressure, at an oxygen content of 0% and 100% before and after the in vivo test. The same probes were implanted in German landrace pigs, which underwent hepatectomy. The mean P(br)O(2) values were recorded every minute. An O(2) challenge with inhalation of 100% O(2) for 10 min was performed 2 h post-abdominal surgery. RESULTS At 0% O(2) content values varied from 0.2 to 7 mmHg, at 100% O(2) content from 130 to 165 mmHg. No difference between probes was found. In vivo tests: Raumedic® showed higher P(br)O(2) values (mean +6.3 mmHg, p < 0.0001) compared with Licox®. During O(2) challenge, both probes responded similarly; however, Raumedic(®) had a 10% higher response amplitude (p < 0.005). After explantation there was again no difference between the two sensors. CONCLUSION Raumedic(®) sensors measured higher P(br)O(2) values. There was no significant difference regarding overall measurement of in vitro accuracy between the two probes, which proved to be robust when used consecutively for longer periods and in different environments.
Collapse
|
122
|
Courchesne E, Karns C, Davis H, Ziccardi R, Carper R, Tigue Z, Chisum HJ, Moses P, Pierce K, Lord C, Lincoln A, Pizzo S, Schreibman L, Haas R, Akshoomoff N, Courchesne R. Unusual brain growth patterns in early life in patients with autistic disorder: An MRI study. Neurology 2011. [DOI: 10.1212/01.wnl.0000399191.79091.28] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
123
|
Schroeder T, Haas R, Kobbe G. Treatment of graft-versus-host disease with monoclonal antibodies and related fusion proteins. Expert Rev Hematol 2011; 3:633-51. [PMID: 21083479 DOI: 10.1586/ehm.10.46] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Allogeneic hematopoietic stem cell transplantation has evolved from an experimental treatment approach to a widely used, curative therapy to treat malignant and nonmalignant diseases of the hematopoietic system. Despite advances in donor selection, conditioning regimens and supportive care, acute and chronic graft-versus-host disease (GvHD) remain a major cause of morbidity and mortality. Steroids are the standard first-line treatment and are able to control GvHD in approximately 50% of patients. Those who fail on steroids have a poor long-term prognosis. Therefore, a large number of drugs and procedures have been evaluated as second-line therapy. Monoclonal antibodies have increasingly been used to treat malignancy and autoimmune disease during the last 20 years. Their unique ability to target specific antigens theoretically enables them to directly interfere with cellular mechanisms that are involved in GvHD pathology. For this reason, monoclonal antibodies have been studied extensively as a second-line treatment for acute and chronic GvHD. The purpose of this article is to collect published data on clinical trials from the current literature and to give an overview on efficacy and toxicity of monoclonal antibody treatment for GvHD.
Collapse
|
124
|
Zipperer E, Tanha N, Kündgen A, Fox F, Strupp C, Haas R, Gattermann N, Germing U. 55 Independent validation of the MDS Comorbidity Score (MDS-CI). Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70057-1] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
125
|
Klärner V, Schroeder T, Kuendgen A, Safaian N, Weigelt C, Saure C, Kobbe G, Haas R, Gattermann N, Hildebrandt B, Germing U. 304 Clinical impact of trisomy 11 in patients with MDS and AML. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70306-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
126
|
Betgen A, Haas R, El-Mesbahe-Bouzeya N, Minkema D, Wolfrat M, Panneman C, Remeijer P. 996 poster EASYSIM: A PATIENT FRIENDLY VIRTUAL SIMULATION PROCEDURE FOR BONE METASTASES BASED ON DIAGNOSTIC IMAGING. Radiother Oncol 2011. [DOI: 10.1016/s0167-8140(11)71118-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
127
|
Klärner V, Kuendgen A, Schroeder T, Weigelt C, Saure C, Dienst A, Kobbe G, Haas R, Gattermann N, Germing U. 93 Analysis of treatment choices and outcome for MDS and AML patients 60 years and older from the university of Dusseldorf. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70095-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
128
|
Schroeder T, Kündgen A, Kröger N, Platzbecker U, Stadler M, Braulke F, Schlenk R, Zohren F, Haase D, Gattermann N, Haas R, Kobbe G, Germing U. 103 Therapy-related myeloid neoplasms following treatment with radioiodine. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70105-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
|
129
|
Germing U, Neukirchen J, Strupp C, Bach K, Wulfert M, Haas R, Giagounidis A, Aul C, Gattermann N. 57 How to assess the medullary blast count in MDS? Pay attention to the proportion of erythroid cells! Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70059-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
130
|
Nachtkamp K, Stark R, Neukirchen J, Kündgen A, Giagounidis A, Haas R, Gattermann N, Germing U. 153 Analysis of causes of death in 2297 patients with myelodysplastic syndromes. Data from the Dusseldorf MDS registry. Leuk Res 2011. [DOI: 10.1016/s0145-2126(11)70155-2] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
131
|
English P, Blount B, Wong M, Copan L, Olmedo L, Patton S, Haas R, Atencio R, Xu J, Valentin-Blasini L. Direct measurement of perchlorate exposure biomarkers in a highly exposed population: a pilot study. PLoS One 2011; 6:e17015. [PMID: 21394205 PMCID: PMC3048868 DOI: 10.1371/journal.pone.0017015] [Citation(s) in RCA: 11] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/07/2010] [Accepted: 01/18/2011] [Indexed: 11/19/2022] Open
Abstract
Exposure to perchlorate is ubiquitous in the United States and has been found to be widespread in food and drinking water. People living in the lower Colorado River region may have perchlorate exposure because of perchlorate in ground water and locally-grown produce. Relatively high doses of perchlorate can inhibit iodine uptake and impair thyroid function, and thus could impair neurological development in utero. We examined human exposures to perchlorate in the Imperial Valley among individuals consuming locally grown produce and compared perchlorate exposure doses to state and federal reference doses. We collected 24-hour urine specimen from a convenience sample of 31 individuals and measured urinary excretion rates of perchlorate, thiocyanate, nitrate, and iodide. In addition, drinking water and local produce were also sampled for perchlorate. All but two of the water samples tested negative for perchlorate. Perchlorate levels in 79 produce samples ranged from non-detect to 1816 ppb. Estimated perchlorate doses ranged from 0.02 to 0.51 µg/kg of body weight/day. Perchlorate dose increased with the number of servings of dairy products consumed and with estimated perchlorate levels in produce consumed. The geometric mean perchlorate dose was 70% higher than for the NHANES reference population. Our sample of 31 Imperial Valley residents had higher perchlorate dose levels compared with national reference ranges. Although none of our exposure estimates exceeded the U. S. EPA reference dose, three participants exceeded the acceptable daily dose as defined by bench mark dose methods used by the California Office of Environmental Health Hazard Assessment.
Collapse
|
132
|
Dvorak G, Reich KM, Tangl S, Goldhahn J, Haas R, Gruber R. Cortical porosity of the mandible in an osteoporotic sheep model. Clin Oral Implants Res 2010; 22:500-5. [DOI: 10.1111/j.1600-0501.2010.02031.x] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
133
|
Cassens U, Fischer J, Fritsch G, Fruehauf S, Garritsen H, Gebauer W, Haas R, Höffkes HG, Humpe A, Kleine HD, Moog R, Riggert J, Rothe G, Schlenke P, Schmitz G, Tonn T, Wörmann B, Ziegler B. Durchflußzytometrische Analyse CD34-exprimierender Hämatopoetischer Zellen in Blut und Zytaphereseprodukten. Transfus Med Hemother 2010. [DOI: 10.1159/000223331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
|
134
|
Kobbe G, Bruns I, Schroeder T, Czibere A, Warnecke J, Hieronimus N, Safaian N, Kondakci M, Saure C, Germing U, Haas R, Fenk R. A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma. Ann Oncol 2010; 21:1898-1904. [DOI: 10.1093/annonc/mdq059] [Citation(s) in RCA: 20] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
135
|
Schroeder T, Ruf L, Bernhardt A, Hildebrandt B, Aivado M, Aul C, Gattermann N, Haas R, Germing U. Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol 2010; 21:2267-2271. [PMID: 20439346 DOI: 10.1093/annonc/mdq233] [Citation(s) in RCA: 24] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
BACKGROUND Patients not fulfilling minimal criteria for myelodysplastic syndromes (MDS) but presenting with persisting cytopenia(s) not attributable to a haematological or non-haematological disease are defined as 'idiopathic cytopenia of undetermined significance' (ICUS). DESIGN AND METHODS We retrospectively analysed 67 of 3504 patients from our MDS Registry fulfilling the criteria for ICUS. Furthermore, we used the human androgen receptor gene-based assay (HUMARA) to look for clonality. RESULTS Of all 67 patients, 66% had unilineage, 18% bilineage and 12% trilineage cytopenias. The majority of patients (67%) presented with anaemia. Median overall survival was 44 months (range: 1-199 months). In the entire group, eight patients (12%) developed acute myeloid leukaemia (AML). Of the 23 patients eligible for HUMARA, 17 had non-clonal X-chromosome inactivation patterns, while 6 patients showed clonal patterns. Two of these six patients developed AML indicating that a clonal stem cell disorder was the reason for the anteceding cytopenia, while there was no AML observed among the 17 patients with non-clonal patterns (P = 0.013). CONCLUSIONS Since some of the ICUS patients had a clonal bone marrow disease when presenting with cytopenia(s) and 8 of 67 patients with ICUS later developed AML, we recommend to follow these patients thoroughly. As demonstrated here, HUMARA can facilitate the discrimination between ICUS and a 'manifest' MDS.
Collapse
|
136
|
Michael M, Bruns I, Bölke E, Zohren F, Czibere A, Safaian NN, Neumann F, Haas R, Kobbe G, Fenk R. Bendamustine in patients with relapsed or refractory multiple myeloma. Eur J Med Res 2010; 15:13-9. [PMID: 20159666 PMCID: PMC3351842 DOI: 10.1186/2047-783x-15-1-13] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/02/2022] Open
Abstract
Objective In patients with multiple myeloma, bendamustine monotherapy is effective as 1st and 2nd line therapy. However, data for patients with advanced multiple myeloma is rare. Methods In this retrospective analysis we have identified 39 patients with relapsed or refractory multiple myeloma by means of case research, who have been treated at our institution with bendamustine as salvage therapy. After in median 2 lines of prior therapy (range:1-5) patients received in median 3 (range: 1-10) cycles of bendamustine. Bendamustine dosage was 80-150 mg on day 1+2 of a monthly cycle. Bendamustine was administered as monotherapy in 39% of patients, whereas 61% received concomitant steroids. Results Toxicity was mild to moderate. Response rates were as follows: 3% vgPR, 33% PR, 18% MR, 26% SD and 20% PD. The median event-free and overall survival were 7 and 17 months, respectively. Conclusions In conclusion, in patients with advanced multiple myeloma bendamustine is effective and associated with mild toxicity. Therefore, the role of bendamustine in patients with multiple myeloma should be investigated in further clinical trials.
Collapse
|
137
|
Czibere A, Bruns I, Kröger N, Platzbecker U, Lind J, Zohren F, Fenk R, Germing U, Schröder T, Gräf T, Haas R, Kobbe G. 5-Azacytidine for the treatment of patients with acute myeloid leukemia or myelodysplastic syndrome who relapse after allo-SCT: a retrospective analysis. Bone Marrow Transplant 2009; 45:872-6. [DOI: 10.1038/bmt.2009.266] [Citation(s) in RCA: 93] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
138
|
Dvorak G, Reich K, Tangl S, Lill C, Gottschalk-Baron M, Watzek G, Gruber R, Haas R. Periodontal histomorphometry and status of aged sheep subjected to ovariectomy, malnutrition and glucocorticoid application. Arch Oral Biol 2009; 54:857-63. [DOI: 10.1016/j.archoralbio.2009.05.010] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/05/2008] [Revised: 04/08/2009] [Accepted: 05/26/2009] [Indexed: 11/16/2022]
|
139
|
Haas R, Betgen A, Sonke J. 9412 Cone-beam CT guidance for set-up verification in extremity soft tissue sarcomas patients. EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)72000-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
140
|
Strupp C, Germing U, Aivado M, Kündgen A, Fenk R, Hünerlitürkoglu A, Kobbe G, Haas R, Gattermann N. The ratio between CD4 + and CD8 + cells in the peripheral blood of patients with hematological malignancies is not altered by thalidomide. Leuk Lymphoma 2009; 46:999-1006. [PMID: 16019550 DOI: 10.1080/10428190500078300] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]
Abstract
Thalidomide is thought to have anti-angiogenic and immunomodulatory properties, including suppression of tumor necrosis factor-alpha, effects on interleukins and interferons, down-regulation of some cell adhesion molecules, and changes in the proportion of lymphocyte subsets. It is unclear whether the clinical response to thalidomide in patients with multiple myeloma (MM), idiopathic myelofibrosis (IM), and myelodysplastic syndromes (MDS) is related to its ability to inhibit angiogenesis or its immunomodulatory effects. We examined the effect of thalidomide on T-lymphocyte subsets in 18 patients with MDS, 6 patients with MM, 4 patients with IM, and 3 patients with angioimmunoblastic lymphoma (AILD). These patients had either a relapse or progressive disease following cytotoxic chemotherapy including high-dose chemotherapy with autologous stem cell support. Thalidomide was first administered at 100 mg/day p.o. and increased to 400 mg/day. T-lymphocyte subsets (CD4+, CD8+) were measured by fluorescence-activated cell sorter (FACS) before and during treatment with thalidomide. Twenty-six of 31 patients responded to thalidomide, most of them achieving partial remission. The median concentration of CD4+ cells was 443/microl, the median of CD8+ cells was 359/microl (CD3 992/microl). In our cohort, no significant changes in absolute numbers or proportions of CD3+ (P = 0.12), CD4+ (P = 0.668), or CD8+ (P = 0.143) cells were observed following the treatment with thalidomide. Although the CD4/CD8 ratio declined from 1.6 to 1.0 during 3 months of thalidomide treatment, this had no statistical significance (P = 0.1). Our findings show that an effect of thalidomide on the T lymphocytes studied is unlikely to be of major importance for the clinical effects.
Collapse
|
141
|
Strupp C, Knipp S, Hartmann J, Gattermann N, Haas R, Germing U. A pilot study of bendamustine in elderly patients with high-risk MDS and AML. Leuk Lymphoma 2009; 48:1161-6. [PMID: 17577779 DOI: 10.1080/10428190701332449] [Citation(s) in RCA: 10] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
We examined the efficacy of bendamustine in 15 pretreated patients (12 men, 3 women, median age 69 years) with acute myeloid leukaemia (AML) or myelodysplastic syndromes (MDS) 3 AML, 5 sAML, 5 CMML II, 1 RAEB II. Patients belonged to the following cytogenetic groups: 3 complex abnormal karyotypes, 7 normal karyotypes, 1 case with 20q- as sole anomaly and 4 single aberrations. The patients received in median two cycles of bendamustine (range 1-5) with a dose of 100 mg/m(2) at Day 1 + 2 (repeated after 28 days). Nine of 15 patients had no side effects of the treatment, six patients suffered from vomiting and epigastric pain as adverse effects of bendamustine. According to the IWG criteria, no complete remission or reduction of transfusions frequency have been observed. Three patients showed no response, one patient with AML died due to progressive disease. In 11 of 12 patients with initial leukocytosis (median 68,975 microl(-1), range 24,000-149,000 microl(-1)), a significant reduction of leukocytosis was achieved with bendamustine with a median duration of 4 weeks. In summary, treatment with bendamustine in patients with high-risk MDS or sAML with leukocytosis can result in a significant reduction of leukocytes, but fails to achieve hematological responses or improvement of transfusions dependency.
Collapse
|
142
|
Preiss A, Bauer A, Berstermann HM, Gerling S, Haas R, Joos A, Lehmann A, Schmalz L, Steinbach K. Advanced high-performance liquid chromatography method for highly polar nitroaromatic compounds in ground water samples from ammunition waste sites. J Chromatogr A 2009; 1216:4968-75. [DOI: 10.1016/j.chroma.2009.04.055] [Citation(s) in RCA: 31] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2009] [Revised: 04/15/2009] [Accepted: 04/17/2009] [Indexed: 10/20/2022]
|
143
|
Goldschmidt H, Hegenbart U, Haas R, Hunstein W. Hematopoietic Progenitor Cell Transplantation in Multiple Myeloma. Oncol Res Treat 2009. [DOI: 10.1159/000218652] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
144
|
Schroeder T, Zohren F, Saure C, Kobbe G, Haas R. Palifermin, a recombinant human keratinocyte growth factor, triggers reactivation of anogenital human papillomavirus infection in a HIV-positive patient with diffuse large cell B-cell non-Hodgkin lymphoma. Bone Marrow Transplant 2009; 44:823-4. [PMID: 19421177 DOI: 10.1038/bmt.2009.81] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|
145
|
Kuendgen A, Strupp C, Nachtkamp K, Hildebrandt B, Gattermann N, Haas R, Germing U. C004 Relevance of prognostic factors in different subgroups of myelodysplastic syndromes. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70042-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
146
|
Froebel J, Hartwig S, Aivado M, Bruns I, Germing U, Kobbe G, Kuendgen A, Eckel J, Lehr S, Haas R, Czibere A. C015 Proteome analysis of platelets from patients with myelodysplastic syndrome shows low expression of proteins required for GPIIb/IIIa function and platelet aggregation. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70053-0] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
147
|
Kuendgen A, Nachtkamp K, Strupp C, Gattermann N, Haas R, Germing U. P124 Matched pair analysis of conventional regimens versus hypomethylating agents for the treatment of higher-risk myelodysplastic syndromes – an analysis from the Duesseldorf MDS Registry. Leuk Res 2009. [DOI: 10.1016/s0145-2126(09)70205-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
|
148
|
Bodechtel G, Haas R, Joppich G, Lennartz H, Pette H, Siegert R. Gesundheitsschäden nach oraler Impfung mit dem Poliomyelitis-Impfstoff Typ I von Sabin1. Dtsch Med Wochenschr 2009. [DOI: 10.1055/s-0028-1112300] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
149
|
Bruns I, Czibere A, Fischer JC, Roels F, Cadeddu RP, Buest S, Bruennert D, Huenerlituerkoglu AN, Stoecklein NH, Singh R, Zerbini LF, Jäger M, Kobbe G, Gattermann N, Kronenwett R, Brors B, Haas R. The hematopoietic stem cell in chronic phase CML is characterized by a transcriptional profile resembling normal myeloid progenitor cells and reflecting loss of quiescence. Leukemia 2009; 23:892-9. [PMID: 19158832 DOI: 10.1038/leu.2008.392] [Citation(s) in RCA: 63] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
Abstract
We found that composition of cell subsets within the CD34+ cell population is markedly altered in chronic phase (CP) chronic myeloid leukemia (CML). Specifically, proportions and absolute cell counts of common myeloid progenitors (CMP) and megakaryocyte-erythrocyte progenitors (MEP) are significantly greater in comparison to normal bone marrow whereas absolute numbers of hematopoietic stem cells (HSC) are equal. To understand the basis for this, we performed gene expression profiling (Affymetrix HU-133A 2.0) of the distinct CD34+ cell subsets from six patients with CP CML and five healthy donors. Euclidean distance analysis revealed a remarkable transcriptional similarity between the CML patients' HSC and normal progenitors, especially CMP. CP CML HSC were transcriptionally more similar to their progeny than normal HSC to theirs, suggesting a more mature phenotype. Hence, the greatest differences between CP CML patients and normal donors were apparent in HSC including downregulation of genes encoding adhesion molecules, transcription factors, regulators of stem-cell fate and inhibitors of cell proliferation in CP CML. Impaired adhesive and migratory capacities were functionally corroborated by fibronectin detachment analysis and transwell assays, respectively. Based on our findings we propose a loss of quiescence of the CML HSC on detachment from the niche leading to expansion of myeloid progenitors.
Collapse
|
150
|
Bruennert D, Czibere A, Bruns I, Kronenwett R, Gattermann N, Haas R, Neumann F. Early in vivo changes of the transcriptome in Philadelphia chromosome-positive CD34+ cells from patients with chronic myelogenous leukaemia following imatinib therapy. Leukemia 2008; 23:983-5. [DOI: 10.1038/leu.2008.337] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
|